Driver Oncogenes in Advanced NSCLC - Current and Future Perspectives

Details & Video

Program Time: 60 minutes (flexible participation time)
Target Audience: Medical Oncologists
Program available until: This program does not expire
Program Preview
Click image above to play the program preview.
To watch the full program, please login or register

Overview & Objectives

Driver Oncogenes in Advanced NSCLC

Target Audience: Medical Oncologists.

By participating in this educational program, health care providers will be able to:
  1. Apply guideline recommendations for molecular testing in advanced NSCLC
  2. Integrate available clinical evidence for the use of targeted therapies in the first and second-line management of patients with actionable driver mutations
  3. Assess emerging molecular testing modalities and their implications for the management of patients with advanced NSCLC



Accreditation

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization. A scientific planning committee developed the learning objectives based on a completed needs assessment of the target audience, ensured the content provided a balanced view across all relevant options related to the content area, and acted independently of the program sponsor. Hoffmann-La Roche Limited provided support for this HCP learning program.

Credits:
Specialist participants may claim Section 2 credits (up to 2 credits per hour) for having completed this programs reflective exercise. Participation to be reported as a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.

Planning Committee & Faculty

Planning Committee & Faculty

Jeff Rothenstein
Faculty
Jeff Rothenstein
MD, FRCPC

View disclosures

Oshawa, ON
Normand Blais
Normand Blais
MD, FRCPC

View disclosures

Montreal, QC
Randeep Sangha
Randeep Sangha
MD, FRCPC

View disclosures

Edmonton, AB
Zhaolin Xu
Zhaolin Xu
MD, FRCPC, FCAP

View disclosures

Halifax, NS

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction1:33
Molecular testing in advanced NSCLC12:18
EGFR mutation11:43
ALK rearrangement16:27
ROS1 rearrangement4:01
BRAF mutation3:11
Emerging molecular testing modalities7:38
Summary1:10


Sponsorship

CCRN sm

This activity was made possible through support provided by Hoffmann-La Roche Limited

Links & Resources

Links & Resources:

  • Adapted from Bubendorf L, Lantuejoul S. Eur Respir Rev. 2017 Jun 28;26(144). 2. Chan BA, Hughes BGM. Transl Lung Cancer Res 2015;4(1):36-54.
  • Kris MG, Johnson BE, Berry LD, et al. JAMA 2014; 311:1998–2006.
  • 1L, first line; 2L, second line; ALK, anaplastic lymphoma kinase; CNS, central nervous system; CE, cost-effectiveness; EGFRm, EGFR sensitizing mutations, HC, Health Canada; mets, metastases; pCODR, pan-Canadian Oncology Drug Review
  • Directed search 5/11/2018: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
  • Directed search 5/11/2018: https://www.cadth.ca/pcodr/find-a-review
  • 1L, first line; 2L, second line; ALK, anaplastic lymphoma kinase; CNS, central nervous system; CE, cost-effectiveness; HC, Health Canada; mets, metastases; pCODR, pan-Canadian Oncology Drug Review
  • Directed search 5/11/2018: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
  • Directed search 5/11/2018: https://www.inesss.qc.ca/en.html
  • Lindeman NI, Cagle PT, Beasley MB, et al. Arch Pathol Lab Med. 2013;137(6):828–860. (CAP/IASLC/AMP)
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Leighl NB, Rekhtman N, Biermann WA, et al. J Clin Oncol 2014; 32:3673-3679. (ASCO)
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol 2018; 36:1-11. (ASCO)
  • Melosky B, Blais N, Cheema P, et al. Curr Oncol. 2018;25(1):73-82. (Canada)
  • Pao W, Miller VA. J Clin Oncol. 2005;23:2556-2568.
  • Gazdar AF. Oncogene 2009;28:S24-S31.
  • Solomon B, et al. J Thorac Oncol 2009; 4:1450–1454.
  • Soda M, et al. Nature 2007; 448:561-566.
  • Gainor JF, et al. Clin Cancer Res 2013; 19(15):4273-4281
  • Bubendorf L, et al. Virchows Arch. 2016; 469(5): 489–503.
  • Rossi G, et al. Lung Cancer (Auckl). 2017; 8::45–55.
  • Williams AS, et al. Virchows Arch. 2016; 469(5):533-540.
  • Greer W, et al. Can J Pathol 2015; 7(1):20-26.
  • Caparica R, et al. Crit Rev Oncol Hematol. 2016; 101:32–39.
  • Lindeman NI, Cagle PT, Beasley MB, et al. Arch Pathol Lab Med. 2013;137(6):828–860. (CAP/IASLC/AMP)
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol 2018; 36:1-11. (ASCO)
  • Non-small Cell Lung Cancer Version 3.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed March 3, 2018
  • Roche EGFR Mutation Test Approved in Canada. Genome web, Published March 2017. https://www.genomeweb.com/pcr/roche-egfr-mutation-test-approved-canada#.WrkfJmNTVos. Accessed March 26, 2018
  • Mills F, Leighl N, Shum D, Koester O. Reimbursement Perspectives on Precision Medicine. CADTH Symposium 2017. https://www.cadth.ca/sites/default/files/symp-2017/presentations/april24-2017/Concurrent-Session-C2-Reimbursement- Perspectives-on-Precision-Medicine.pdf Accessed March 26, 2018.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Melosky B, Blais N, Cheema P, Curr Oncol. 2018;25(1):73-82.
  • Tsao MS, Torlakovic E, Bigras G, et al. Annal of Oncol 2017; 28(suppl_2): LBA1.
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol. 2018; 36:1-11. (ASCO)
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Travis WD, Brambilla E, Noguchi M, et al. J Thorac Oncol 2011;6(2):244-285.
  • Confavreau CB, Girard N, Pialat JB, et al. Bonekey Rep. 2014;3:580.
  • Lindeman NI, Cagle PT, Beasley MB, et al. Arch Pathol Lab Med. 2013;137(6):828–860. (CAP/IASLC/AMP)
  • Lim C, Tsao MS, Le LW, et al. Ann Oncol. 2015; 26:1415-1421.
  • Lim C, Sekhon HS, Cutz JC, et al. Current Oncol. 2017;24(2):103-110.
  • Policy on molecular testing in Lung Cancer. Lung Cancer Canada. http://www.lungcancercanada.ca/LungCancerCanada/media/ Documents/Infosheets/LCC_Policy-on-Molecular-Testing-in-Lung-Cance_2014.pdf Accessed March 15, 2018.
  • Hanna N, Johnson D, Temin S, et al. J Clin Oncol. 2017;35(30):3484-3515. (ASCO)
  • Non-small Cell Lung Cancer Version 3.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed March 3, 2018
  • Sullivan I, Planchard D. Front Med (Lausanne) 2017;3:76.
  • Directed search 11/5/2018 : https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
  • Directed search 11/5/2018 : https://www.cadth.ca/pcodr/find-a-review;
  • Castellanos E, Feld, E, Horn, L. Journal of Thoracic Oncology. 2016;12(4):612-623.
  • Sullivan I, Planchard D. Front Med (Lausanne) 2017;3:76.
  • Directed search 11/5/2018: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
  • Directed search 11/5/2018: https://www.inesss.qc.ca/en.html
  • Castellanos E, Feld, E, Horn, L. Journal of Thoracic Oncology. 2016;12(4):612-623.
  • NCT02186301 Zhang Y, Sheng J, Yang Y, et al. Oncotarget 2016;7(15):20093-20108.
  • Barnes TA, O’Kane GM, Vincent MD, Leighl NB. Front Oncol. 2017; 7: 113.
  • Soria JC, Ohe Y, Vansteenkiste J, et al. N Engl J Med. 2018;378(2):113-125rociletinib termintated PhaseII/III study
  • Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Molecular Cancer. 2018;17:38.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol 2018; 36:1-11. (ASCO)
  • National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2018). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 6, 2018
  • 1. Gandara DR, Li T, Lara PN, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014; 15(1):1-6.
  • 2. Yap TA, Macklin-Doherty A, Popat S. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer 2017; 70:12-21.
  • 3. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013; 8:346-351.
  • 4. Inomata M, Shukuya T, Takahashi T, et al. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Res 2011;31(12): 4519e23.
  • 5. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7(12):1807e14.
  • 6. Shukuya T, Takahashi T, Naito T, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 2011;74(3):457e61.
  • 7. Khalifa J, Amini A, Popat S, et al. Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted therapies. J Thorac Oncol 2016;11(10):1627e43.
  • 8. Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Thorac Oncol. 2013;31:895-902.
  • OTHER: Arbour KC, Kris MG, Riely GJ, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 2018;124:105-9
  • 1. Gandara DR, Li T, Lara PN, et al. Clin Lung Cancer. 2014; 15(1):1-6.
  • 2. Barnes TA, O’Kane GM, Vincent MD, et al. Front Oncol. 2017; 7: 113.
  • 3. Yap TA, Macklin-Doherty A, Popat S. Eur J Cancer 2017; 70:12-21.
  • 4. Park K, Ahn M, Yu C, et al. Ann Oncol 2014;25(Suppl 4: 12230):iv426–7.
  • 5. Horn L, Gettinger S, Camidge DR. Lung Cancer. 2017;113:51-58.
  • Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672-1682.
  • Robichaux JP, et al. Nat Med. 2018 May; 24(5): 638–646.
  • Clinical database of 280 patients with EGFR-mutant NSCLC, 129 patients with classical EGFR mutations (exon 19 deletions and the mutations encoding p.L858R and p.L861Q) and 9 patients with EGFR exon 20 insertion mutations that received single-agent treatment with erlotinib, gefitinib, or afatinib
  • Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med 2017;376:629-40.
  • DCR, disease control rate; DoR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival
  • Mok TS, Wu YL, Ahn MJ, et al. N Engl J Med 2017;376:629-640.
  • Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med 2017;376:629-40.
  • Hanna N, Johnson D, Temin S, et al. J Clin Oncol. 2017;35(30):3484-3515. (ASCO)
  • Non-small Cell Lung Cancer Version 3.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed March 3, 2018
  • Hanna N, Johnson D, Temin S, et al. J Clin Oncol. 2017;35(30):3484-3515. (ASCO)
  • Sullivan I, Planchard D. Ther Adv Med Oncol 2016; 8(1):32-47.
  • Directed search 26/9/2018: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
  • Directed search 26/9/2018: https://www.cadth.ca/pcodr/find-a-review
  • Solomon BJ, Mok T, Kim DW, et al N Engl J Med 2014;371:2167-77.
  • Soria JC, Tan DSW, Chiari R, et al. Lancet 2017; 389:917–929.
  • Peters S, Camidge R, Shaw A, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer. N Engl J Med 2017;377:829-38.
  • Peters S, Camidge R, Shaw A, et al. N Engl J Med 2017;377:829-38.
  • Camidge DR, Peters S, Mok T, et al. Presented at ASCO 2018.
  • Camidge DR, Kim HR, Ahn JC-H. Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. N Engl J Med 2018. 10.1056/NEJMoa1810171
  • Solomon BJ, Mok T, Kim DW, et al N Engl J Med 2014;371:2167-77.
  • Soria JC, Tan DSW, Chiari R, et al. Lancet 2017; 389:917–929.
  • Peters S, Camidge R, Shaw A, et al. N Engl J Med 2017;377:829-38
  • Camidge DR, Peters S, Mok T, et al. Presented at ASCO 2018
  • Camidge DR, Kim HR, Ahn JC-H. N Engl J Med 2018. 10.1056/NEJMoa1810171
  • Solomon BJ, Cappuzzo F, Felip E, et al. J Clin Oncol. 2016; 34(24):2858-2865.
  • Bui KT, Cooper WA, Kao S, Boyer M.Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J Clin Med. 2018 Jul 31;7(8). Gainor JF, Dardaei L, Yoda S, et al. Molecular Mechanisms of
  • Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 Oct;6(10):1118-1133.
  • Shaw AT, Kim TM, Crinò L, et al. Lancet Oncol. 2017;18(7):874-886.
  • Novello S, Mazières J, Oh I, et al. Ann Oncol. 2018 Jun 1;29(6):1409-1416.
  • Ahn M, Camidge DR, Tiseo M, et al. Presented at the IASLC Conference 2017; Abstract OA 05.05.
  • Solomon B, Shaw A, Ou S, et al. Presented at the IASLC Conference 2017; Abstract OA 05.06
  • Hanna N, Johnson D, Temin S, et al. J Clin Oncol. 2017;35(30):3484-3515. (ASCO)
  • Non-small Cell Lung Cancer Version 6.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed Sept 30, 2018.
  • Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer. N Engl J Med. 2014; 371(21): 1963–1971.
  • Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 2017;35:2613-2618.
  • Doebele RC, Ahn M, Siena S, et al. Presented at WCLC 2018.
  • Planchard D, Smit EF, Groen HJM, et al. Lancet Oncol 2017;18:1307-1316.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol 2018; 36:1-11. (ASCO)
  • National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2018). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 6, 2018
  • Melosky B, Blais N, Cheema P, et al. Curr Oncol. 2018;25(1):73-82. (Canada)
  • Directed search of www.clinicatrials.gov. Active, Canada, Lung Cancer, manual review. Accessed October 5th, 2018.
  • Spiegel ML, Goldman JW, Wolf BR, et al. Cancer. 2017;123(24):4800-4807.
  • Salgia R. Future Oncol 2015; 11(3):489-500.
  • Daoud A, Chu QS. Front. Oncol. 2017; 7:222.
  • Travis WD, Brambilla E, Nogushi M, et al. Arch Pathol Lab Med 2013; 137:668–684.
  • Lindeman NI, Cagle PT, Beasley MB, et al. J Thorac Oncol. 2013;8(7):823–859.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Vnencak-Jones CL, et al. My Cancer Genome: Types of Molecular Testing. Published 2016 Feb 8. http://www.mycancergenome.org/
  • Lindeman NI, Cagle PT, Beasley MB, et al. J Thorac Oncol. 2013;8(7):823–859.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Dong L, et al. Curr Genomics 2015;16:253-63.
  • FDA: List of cleared or approved companion diagnostics. Jan 23, 2018. https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
  • Jamal SM, et al. Am J Med Genet 2013;161(5):935-50.
  • MacConaill LE and Garraway LA. J Clin Oncol 2013;31(15):1815-24.
  • Lindeman NI, Cagle PT, Aisner DL, et al. J Mol Diagn. 2018; 20(2):129-159. (CAP/IASLC/AMP)
  • Kalemkerian G, Narula N, Kennedy EB, et al. J Clin Oncol 2018; 36:1-11. (ASCO)
  • National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2018). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 6, 2018
  • Malapelle U, et al. Transl Lung Cancer Res 2016;5(5):505-10.
  • Heitzer E, et al. Clin Chem 2015;61(1):112-23.
  • Busser B, et al. Biomed Res Int 2017;5986129:1-8.
  • Lim C, Sekhon HS, Cutz JC, et al. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. Curr Oncol. 2017 Apr;24(2):103-110